Relation between Different Treatment Modalities and Genomic Damage of End-Stage Renal Failure Patients

Publisher： Karger

E-ISSN： 1423-0143|29|1|10-17

ISSN： 1420-4096

Source： Kidney and Blood Pressure Research, Vol.29, Iss.1, 2006-06, pp. : 10-17

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Genomic Damage and Malignancy in End-Stage Renal Failure: Do Advanced Glycation End Products Contribute?

By  

Kidney and Blood Pressure Research, Vol. 30, Iss. 1, 2006-12 ,pp. : 56-66

Karger

Access to resources Recommend Favorite

Polymorphism of the Angiotensin-Converting Enzyme Gene in End-Stage Renal Failure Patients

By  

Nephron, Vol. 85, Iss. 1, 2000-04 ,pp. : 54-59

Karger

Access to resources Recommend Favorite

End-Stage Renal Failure Patients Requiring Renal Replacement Therapy in the Intensive Care Unit: Incidence, Clinical Features, and Outcome

By  

Blood Purification, Vol. 21, Iss. 2, 2003-02 ,pp. : 170-175

Karger

Access to resources Recommend Favorite

The Pattern of Inflammation and a Potential New Clinical Meaning and Usefulness of C-Reactive Protein in End-Stage Renal Failure Patients

By  

Kidney and Blood Pressure Research, Vol. 28, Iss. 1, 2005-01 ,pp. : 55-61

Karger

Access to resources Recommend Favorite

Effect of Dialysis on Plasma Total Antioxidant Capacity and Lipid Peroxidation Products in Patients with End-Stage Renal Failure

By  

Blood Purification, Vol. 21, Iss. 3, 2003-06 ,pp. : 209-212

Karger

Access to resources Recommend Favorite